Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) stock closed at 6.64 per share at the end of the most recent trading day (a -0.75% change compared to the prior day closing price) with a volume of 2.73M shares and market capitalization of 682.46M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 76 people. Catalyst Pharmaceuticals Inc. CEO is Patrick J. McEnany.

The one-year performance of Catalyst Pharmaceuticals Inc. stock is 13.39%, while year-to-date (YTD) performance is -1.92%. CPRX stock has a five-year performance of 133.8%. Its 52-week range is between 4.81 and 8.645, which gives CPRX stock a 52-week price range ratio of 47.72%

Catalyst Pharmaceuticals Inc. currently has a PE ratio of 15.90, a price-to-book (PB) ratio of 3.12, a price-to-sale (PS) ratio of 4.17, a price to cashflow ratio of 11.10, a PEG ratio of 2.32, a ROA of 20.80%, a ROC of 22.13% and a ROE of 23.17%. The company’s profit margin is 29.29%, its EBITDA margin is 39.10%, and its revenue ttm is $153.72 Million , which makes it $1.50 revenue per share.

Of the last four earnings reports from Catalyst Pharmaceuticals Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.17 for the next earnings report. Catalyst Pharmaceuticals Inc.’s next earnings report date is 08th Aug 2022.

The consensus rating of Wall Street analysts for Catalyst Pharmaceuticals Inc. is Strong Buy (1), with a target price of $11.6, which is +74.70% compared to the current price. The earnings rating for Catalyst Pharmaceuticals Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Catalyst Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Catalyst Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.70, ATR14 : 0.34, CCI20 : -39.86, Chaikin Money Flow : 0.07, MACD : -0.18, Money Flow Index : 32.90, ROC : -7.39, RSI : 45.33, STOCH (14,3) : 38.89, STOCH RSI : 0.86, UO : 51.77, Williams %R : -61.11), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Catalyst Pharmaceuticals Inc. in the last 12-months were: Alicia Grande (Option Excercise at a value of $530 400), Alicia Grande (Sold 113 000 shares of value $640 779 ), Brian Elsbernd (Option Excercise at a value of $0), Charles B. O'Keeffe (Option Excercise at a value of $156 000), David S. Tierney (Option Excercise at a value of $206 600), David S. Tierney (Sold 70 000 shares of value $303 895 ), Donald A. Denkhaus (Option Excercise at a value of $268 700), Gary Ingenito (Option Excercise at a value of $0), Gary Ingenito (Sold 7 224 shares of value $50 474 ), Patrick J. McEnany (Option Excercise at a value of $936 000), Patrick J. McEnany (Sold 199 493 shares of value $1 147 646 ), Philip H. Coelho (Option Excercise at a value of $156 000), Philip H. Coelho (Sold 28 540 shares of value $157 780 ), Richard J. Daly (Option Excercise at a value of $167 500), Steven R. Miller (Option Excercise at a value of $577 200), Steven R. Miller (Sold 120 963 shares of value $694 056 )